Rival Research
Added 2021-04-21 13:03:58 +0000 UTCIn response to the Benson&Benson Exapinsol initiative, SpiralLevitica has initiated its own targeted body tissue treatment program. With our previous research into biotech weaponry, we were able to repurpose another program to immediately make up lost ground and are forging ahead with this groundbreaking technology. Our test subject is a 26 year old Caucasian female who is 5'9" and weighs 132lbs. She is athletic and has a low bodyfat percentage. She has elected to receive Enlarginate treatments in two areas of her body, her breasts and her posterior. We have administered a low dosage at first to see how she responds and are very pleased with the results. She has progressed from a 32B into a 32DD, gaining 3 inches of bust size and 4 inches of girth to her hips. This balanced controlled response pleases us and we will be administering a larger dose for her second trial... after she is fitted with a new larger bra and panties.
